Real-world effectiveness, drug survival and safety of risankizumab over a period of 2 years in 158 patients with moderate-to-severe plaque psoriasis
J Eur Acad Dermatol Venereol
.
2024 Mar 20.
doi: 10.1111/jdv.19956.
Online ahead of print.
Authors
Natalia Rompoti
1
,
Irene Stefanaki
1
,
Pantelis Panagakis
1
,
Marina Papoutsaki
1
,
Maria Politou
1
,
Charitomeni Vavouli
1
,
Angeliki Befon
1
,
Fiori Kousta
1
,
Eleni Lazou
1
,
Maria Zaimi
1
,
Ioannis-Alexios Koumprentziotis
1
,
Vasiliki Chasapi
1
,
Dimitrios Rigopoulos
1
,
Alexander Stratigos
1
,
Electra Nicolaidou
1
Affiliation
1
1st Department of Dermatology-Venereology, Medical School, National and Kapodistrian University of Athens, "A. Sygros" Hospital for Skin and Venereal Diseases, Athens, Greece.
PMID:
38506605
DOI:
10.1111/jdv.19956
No abstract available
Publication types
Letter